Aponvie : first intravenous P/neurokinin-1 (NK) receptor antagonist
- It was a brilliant idea that it significantly enhanced the efficacy of the generic drug by changing the route of administration.
- Aponvie’s fast onset of action, and half-life in human brain and convenience for patients (compliance perspective) seem very strong.
- However, the market penetration of Aponvie will be deecided by its price becausue generic drugs are much cheaper.
- Cancer patients spend high cost for their treatments and suffer from bills from hospitals and pharmacies. I am not confident they have enough room in their pockets to spend extra money for treating side effects of chemotherapy because side effects are just side effects, not directly related to “life or death matter.”
Zynrelef : postoperative pain reliever
- Zynrelef seems very promosinf and sounds really a next blockbuster because it can alternate opoids.
- Zynrelef can be injected in the surgery wound and its pain relieving effect can last up to 72 hours, and patients will feel nothing or less pain. 참고 자료:
https://www.fiercepharma.com/pharma/heron-scores-fda-go-ahead-aponvie-iv-alternative-pills-postoperative-nausea
Heron scores FDA go-ahead for Aponvie, an IV alternative to pills for postoperative nausea
Heron Therapeutics has two drugs on the market to prevent the nausea and vomiting associated with chemotherapy. Now, it has one to prevent the sickness that often comes after surgery. | On Friday, the FDA approved Aponvie, which becomes the first intraveno
www.fiercepharma.com
http://www.newsmp.com/news/articleView.html?idxno=214784
美FDA, 헤론 비마약성 진통제 진렐레프 승인 - 의약뉴스
미국 생명공학기업 헤론 테라퓨틱스(Heron Therapeutics)가 3번째 시도 만에 미국 식품의약국(FDA)으로부터 비마약성 마취제 진렐레프(Zynrelef, 부피바카인/멜록시캄)의 승인을 획득했다.헤론 테라퓨틱
www.newsmp.com
Heron Therapeutics Announces Approval of ZYNRELEF® by Health Canada for the Management of Postoperative Pain
/PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing...
www.prnewswire.com
'일 > 제약 바이오' 카테고리의 다른 글
| Safety와 Tolerability의 차이 (feat. Chat GPT) (0) | 2023.07.04 |
|---|---|
| 고양이 관절염 항체 치료제 Solensia (FDA 최초로 승인한 동물용 항체 치료제) (0) | 2022.09.22 |
| Qiagen + Neuron23 NEU-723 파킨슨병 CDx 개발 뉴스 (0) | 2022.09.19 |
| NK cell (Natural killer cell)을 활성화시키는 Combi. therapy (0) | 2022.06.24 |
| Precision BioSciences의 유전자 편집 기술이 CRISPR의 대항마 될까? (0) | 2022.05.27 |